SMMT
Summit TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
SMMT vs peer average
46/100
SMMT vs. peer average (C vs. C)
Grade spread
A 2 · B 5 · C 1 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
MRK is the first available peer comparator.
Direct NSCLC immuno-oncology comparator because Summit's HARMONi-3 is designed against pembrolizumab plus chemotherapy, while Summit's 10-K also identifies Merck's sacituzumab tirumotecan among Phase III competitive candidates in first-line NSCLC [#10-K-2026-02-23].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SMMT
Summit Therapeutics
MRK
Merck
Grade
C
B
Momentum
79
91
Value
41
61
Sentiment
60
47
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Constructive
Grade position vs MRK
SMMT / MRK
Grade Position
In line
SMMT vs. peer average (C vs. C)
46/100
Momentum
79
MRKValue
41
MRKSentiment
60
SMMTRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SMMT
MRK is the first peer returned for this comparison set.